Effect and mechanism of Jingangteng capsules in the treatment of non-alcoholic fatty liver disease based on gut microbiota and metabolomics
- VernacularTitle:基于肠道菌群和代谢组学研究金刚藤胶囊治疗非酒精性脂肪肝的作用及机制
- Author:
Shiyuan CHENG
1
;
Yue XIONG
1
;
Dandan ZHANG
2
;
Jing LI
1
;
Zhiying SUN
1
;
Jiaying TIAN
1
;
Li SHEN
1
;
Yue SHEN
1
;
Dan LIU
1
,
3
;
Qiong WEI
1
;
Xiaochuan YE
1
Author Information
1. Hubei Provincial Key Laboratory of Chinese Medicinal Material Resources and Chinese Medicine Chemistry，School of Pharmacy，Hubei University of Chinese Medicine，Wuhan 430065，China
2. Provincial Key Laboratory for Cardio-Cerebrovascular Diseases in Diabetes Mellitus，School of Pharmacy，Faculty of Medicine，Hubei University of Science and Technology，Hubei Xianning 437099，China
3. Hubei Shizhen Laboratory，Wuhan 430065，China
- Publication Type:Journal Article
- Keywords:
Jingangteng capsules;
non-alcoholic fatty liver disease;
gut microbiota;
metabolomics;
NF-κB/NLRP3 signaling
- From:
China Pharmacy
2025;36(11):1340-1347
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the effect and mechanism of Jingangteng capsules in the treatment of non-alcoholic fatty liver disease （NAFLD）. METHODS Thirty-two SD rats were randomly divided into normal group and modeling group. The modeling group was fed a high-fat diet to establish a NAFLD model. The successfully modeled rats were then randomly divided into model group， atorvastatin group[positive control， 2 mg/（kg·d）]， and Jingangteng capsules low- and high-dose groups [0.63 and 2.52 mg/（kg·d）]， with 6 rats in each group. The pathological changes of the liver were observed by hematoxylin-eosin staining and oil red O staining. Enzyme-linked immunosorbent assay was performed to determine the serum levels of triglycerides （TG）， total cholesterol （TC）， high-density lipoprotein cholesterol （HDL-C）， low-density lipoprotein cholesterol （LDL-C）， alanine transaminase （ALT）， aspartate transaminase （AST）， tumour necrosis factor-α （TNF-α）， interleukin-1β （IL-1β）， IL-6， IL-18. 16S rDNA amplicon sequencing and metabolomics techniques were applied to explore the effects of Jingangteng capsules on gut microbiota and metabolisms in NAFLD rats. Based on the E-mail：591146765@qq.com metabolomics results， Western blot analysis was performed to detect proteins related to the nuclear factor kappa-B （NF-κB）/NOD-like receptor family protein 3 （NLRP3） signaling pathway in the livers of NAFLD rats. RESULTS The experimental results showed that Jingangteng capsules could significantly reduce the serum levels of TG， TC， LDL-C， AST， ALT， TNF-α， IL-1β， IL-6， IL-18， while increased the level of HDL-C， and alleviated the hepatic cellular steatosis and inflammatory infiltration in NAFLD rats. They could regulate the gut microbiota disorders in NAFLD rats， significantly increased the relative abundance of Romboutsia and Oscillospira， and significantly decreased the relative abundance of Blautia （P＜0.05）. They also regulated metabolic disorders primarily by affecting secondary bile acid biosynthesis， fatty acid degradation， O-antigen nucleotide sugar biosynthesis， etc. Results of Western blot assay showed that they significantly reduced the phosphorylation levels of NF-κB p65 and NF-κB inhibitor α， and the protein expression levels of NLRP3， caspase-1 and ASC （P＜0.05 or P＜0.01）. CONCLUSIONS Jingangteng capsules could improve inflammation， lipid accumulation and liver injury in NAFLD rats， regulate the disorders of gut microbiota and metabolisms， and inhibit NF-κB/NLRP3 signaling pathway. Their therapeutic effects against NAFLD are mediated through the inhibition of the NF-κB/NLRP3 signaling pathway.
